ICVX - Icosavax, Inc. Stock Price, Fair Value and News

$15.31

Market Closed

ICVX Stock Valuation Analysis

Valuation

Max Portfolio %

ICVX Price Action

ICVX RSI Chart

ICVX Stock Valuation Analysis

Valuation

Max Portfolio %

ICVX Valuation

ICVX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ICVX Fundamentals

ICVX Revenue

ICVX Earnings

ICVX Profitability

ICVX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	6.4M	4.5M	2.7M	582.0K
2021	3.2M	4.7M	6.3M	7.8M
2020	0	0	0	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Icosavax, Inc.

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.

CEO	Mr. Adam K. Simpson
WEBSITE	https://icosavax.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	60